Strengthening the Opegane Product Lineup through the Launch of Shellgan
First written in FY2017-Q1. 7 of 19 entries say "Advanced", first in FY2017-Q2. Latest entry: FY2024-Q3.
3 other companies' latest entry also says "Advanced".
- FY2024-Q3AdvancedAnnual report
「The OPEGAN ophthalmic surgical adjunct products saw deliveries to medical institutions increase, supported by the market's growth trend accompanying the aging population and the impact of limited shipments of competing products. Despite the impact of the NHI price reduction, our sales increased on higher shipment volumes.」
Deliveries of the OPEGAN products increased against the backdrop of the market's growth trend and limited shipments of competing products, and our sales increased on higher shipment volumes despite the impact of the NHI price reduction. - FY2023-Q3AdvancedAnnual report
「The OPEGAN ophthalmic surgical adjunct products saw deliveries to medical institutions increase as the market began returning to the growth trend that preceded the spread of COVID-19. Despite the impact of the NHI price reduction, our sales increased on higher shipment volumes.」
Against the backdrop of the market returning to its growth trend, deliveries of the OPEGAN products to medical institutions increased, and our sales rose on higher shipment volumes despite the impact of the NHI price reduction. - FY2023-Q2Volumes increased as the market recovered, but sales declined due to inventory adjustments and the NHI price reductionAnnual report
「The OPEGAN ophthalmic surgical adjunct products saw deliveries to medical institutions increase as the impact of COVID-19 subsided and the market began returning to its pre-pandemic growth trend. Our sales declined due to inventory adjustments by our sales partner, in addition to the impact of the NHI price reduction.」
The OPEGAN products saw the market returning to its pre-pandemic growth trend, and deliveries to medical institutions increased. However, our sales declined due to inventory adjustments by our sales partner and the NHI price reduction. - FY2023-Q1Volumes increased as the market recovered, but sales declined due to the NHI price reduction and inventory adjustmentsAnnual report
「The OPEGAN ophthalmic surgical adjunct products saw deliveries to medical institutions increase as the impact of COVID-19 subsided and the market began returning to its pre-pandemic growth trend. Our sales declined due to inventory adjustments by our sales partner, in addition to the impact of the NHI price reduction.」
The OPEGAN products saw the market returning to its pre-pandemic growth trend, and deliveries to medical institutions increased. However, our sales declined due to inventory adjustments by our sales partner and the NHI price reduction. - FY2022-Q2RestatedAnnual report
「For OPEGAN ophthalmic surgical aids, the number of units delivered to medical institutions increased as the market recovered from the contraction caused by the decline in cataract surgeries associated with the spread of COVID-19 in the same period of the previous year. The company's sales declined because shipments in the same period of the previous year were high and because of the impact of cuts to official drug prices.」
Deliveries increased on the rebound from the market contraction and due in part to new medical institutions receiving the products, while sales continued to decline because of the NHI price reduction and the reversal of the high shipment level in the same period of the previous year. - FY2022-Q1Volumes increased as the market recovered, but sales declinedAnnual report
「The OPEGAN ophthalmic surgical adjunct products benefited from a rebound after the market contracted in the same period of the previous year due to a decline in cataract surgeries accompanying the spread of COVID-19, as well as an increase in the number of new medical institutions receiving deliveries. Deliveries to medical institutions increased. However, our sales declined because of the NHI price reduction and the high level of shipments in the same period of the previous year.」
The OPEGAN products saw deliveries to medical institutions increase due in part to the addition of new institutions, while our sales declined because of the NHI price reduction and the reversal of the high shipment level in the same period of the previous year. - FY2021Units delivered and market share expanded amid market contraction; sales remained at the previous-period levelAnnual report
「The OPEGAN ophthalmic surgical adjunct products were affected by a decline in cataract surgeries accompanying the spread of COVID-19, which caused the overall market to contract. However, the number of medical institutions receiving deliveries increased due to shipment adjustments for competing products, driving up deliveries to medical institutions. As a result, our sales were broadly unchanged from the previous fiscal year, with the increase in volume offsetting the NHI price reduction.」
The OPEGAN products saw the market contract as cataract surgeries declined, while deliveries increased as more medical institutions began receiving the products due to shipment adjustments for competing products. Sales were broadly unchanged from the previous fiscal year. - FY2021-Q3AdvancedAnnual report
「Among the OPEGAN ophthalmic surgical aids, the number of cataract surgeries declined as COVID-19 spread, causing the overall market to contract. However, the number of units delivered to medical institutions and market share expanded substantially due to shipment adjustments for competing products. The Company's sales also increased, offsetting the impact of the drug price reduction.」
Despite contraction in the overall market, the number of OPEGAN units delivered to medical institutions and market share expanded against a backdrop of shipment adjustments for competing products, and the Company's sales also increased. - FY2021-Q1Increased amid market contraction due to shipment adjustments for competing productsAnnual report
「Among the OPEGAN ophthalmic surgical aids, the number of cataract surgeries declined as COVID-19 spread, causing the overall market to contract. However, the number of units delivered to medical institutions grew due to the impact of shipment adjustments for competing products, and the Company's sales also increased, offsetting the impact of the drug price reduction.」
While the overall OPEGAN market contracted due to a decline in cataract surgeries, the number of units delivered and the Company's sales increased amid shipment adjustments for competing products. - FY2020-Q3RestatedAnnual report
「Among the OPEGAN ophthalmic surgical aids, the number of units delivered to medical institutions and the Company's sales increased as the overall market expanded and market share was captured from competing products.」
The increase in units delivered and sales of the OPEGAN line, including Shellgan, has continued against a backdrop of market expansion and market share gains from competing products. - FY2019-Q3RestatedAnnual report
「Among the OPEGAN ophthalmic surgical aids, Shellgan continued to grow, increasing the number of units delivered to medical institutions and market share. As a result, the Company's sales were on a par with the same period of the previous year, offsetting the impact of the drug price reduction.」
The OPEGAN line's continued expansion, absorbing the impact of the drug price reduction through Shellgan's growth and market share gains. - FY2019-Q2RestatedAnnual report
「Among the OPEGAN ophthalmic surgical aids, continued growth in Shellgan and expansion of market share meant that the Company's sales were on a par with the same period of the previous year, offsetting the impact of the drug price reduction.」
The OPEGAN line's continued expansion, absorbing the impact of the drug price reduction through Shellgan's growth and market share gains. - FY2018-Q3RestatedAnnual report
「Among the OPEGAN ophthalmic surgical aids, active promotional activities for Shellgan significantly increased the number of units delivered to medical institutions and market share, and the Company's sales also increased.」
The progress of market penetration for the OPEGAN line and expansion in the number of units delivered to medical institutions and market share through Shellgan's promotional activities continue to be reported. - FY2018-Q2AdvancedAnnual report
「Among the OPEGAN ophthalmic surgical aids, active promotional activities for Shellgan, launched in July 2016, drove steady market penetration, significantly increasing the number of units delivered to medical institutions and market share. The Company's sales also increased.」
Active promotional activities for Shellgan drove market penetration of the OPEGAN line and significantly expanded the number of units delivered to medical institutions and market share. - FY2018-Q1RestatedAnnual report
「Market penetration of the ophthalmic surgical aid products in the OPEGAN line progressed steadily as a result of active promotional activities for Shellgan, launched in July 2016. Deliveries to medical institutions and market share expanded, and the company's sales increased.」
Continued market penetration of the OPEGAN line and strengthening of the product lineup through Shellgan's promotional activities. - FY2017AdvancedAnnual report
「Among the OPEGAN ophthalmic surgical aids, market penetration of Shellgan, launched in July 2016 to strengthen the product lineup, is progressing steadily. We will continue to promote wider prescribing by improving product awareness and through other measures.」
Market penetration of Shellgan progressed steadily, expanding both the number of OPEGAN units delivered to medical institutions and market share. - FY2017-Q3AdvancedAnnual report
「Among the OPEGAN ophthalmic surgical aids, market penetration of Shellgan, launched in July 2016, progressed steadily, increasing the number of units delivered to medical institutions. The Company's sales also increased, offsetting the impact of the drug price reduction.」
Steady market penetration of Shellgan and increases in the number of units delivered to medical institutions and the Company's sales were reported. - FY2017-Q2AdvancedAnnual report
「Among the OPEGAN ophthalmic surgical aids, Shellgan, launched in July 2016 to strengthen the product lineup, made a strong start, and the number of units delivered to medical institutions increased.」
The strong start following the launch of Shellgan and the increase in units delivered to medical institutions were reported. - FY2017-Q1First statedAnnual report
「In July 2016, we launched Shellgan, an ophthalmic surgical aid, to strengthen the OPEGAN product lineup. Going forward, we will promote expanded sales together with sales partner Santen Pharmaceutical.」
The first mention was made of measures to expand sales of the OPEGAN line together with Santen Pharmaceutical following the launch of Shellgan, an ophthalmic surgical aid, in July 2016.